期刊
TRENDS IN MOLECULAR MEDICINE
卷 25, 期 2, 页码 149-163出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2018.12.006
关键词
-
资金
- German Research Foundation (DFG)
- German Federal Ministry of Education and Research (BMBF) through the BSRT [GSC203]
- BCRT
- BMBF (DIMEOS) [01EC1402B]
- DFG [FOR2165, GE2512/2-2]
- EU Horizon 2020 Research and Innovation Programme [733006, 779293]
- Fraternal Order of Eagles Diabetes Research Center
- Straub Foundation
- Swedish Research Council [K2014-64X-05971-34-4]
- Swedish Cancer Society [CAN2013/671]
- Cancer Society in Stockholm [111293]
- Karolinska Institutet
- H2020 Societal Challenges Programme [733006, 779293] Funding Source: H2020 Societal Challenges Programme
Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据